Market revenue in 2023 | USD 8.8 million |
Market revenue in 2030 | USD 31.3 million |
Growth rate | 19.9% (CAGR from 2023 to 2030) |
Largest segment | Cell & gene therapy |
Fastest growing segment | Cell & Gene Therapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Cell & Gene Therapy, Immunotherapy |
Key market players worldwide | Charles River Laboratories International Inc, Boehringer Ingelheim, Thermo Fisher Scientific Inc, Lonza Group Ltd, Viva Biotech, VGXI, PlasmidFactory, BioCina, TriLink BioTechnologies, Esco Aster |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to plasmid dna contract manufacturing market will help companies and investors design strategic landscapes.
Cell & gene therapy was the largest segment with a revenue share of 60.23% in 2023. Horizon Databook has segmented the France plasmid dna contract manufacturing market based on cell & gene therapy, immunotherapy covering the revenue growth of each sub-segment from 2018 to 2030.
The growing prevalence of chronic diseases, such as cardiovascular, infectious, & genetic diseases and cancer, is the primary factor driving the demand for therapies. In addition, the use of pDNA in manufacturing vaccines impels demand in the country.
According to RaDiCo, a French national research program, in France, 3.0 million people are affected by rare diseases, while at least 26 to 30 million people are affected in Europe. More than one-third of all infant fatalities are caused by these disorders, which are a serious medical issue.
However, genetic therapies are expected to revolutionize the treatment of rare genetic diseases, which would further increase the demand for pDNA contract manufacturing market due to its wide application in gene therapies.
Horizon Databook provides a detailed overview of country-level data and insights on the France plasmid dna contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into France plasmid dna contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account